ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$27.52
-0.90% today
Updated 2026-04-29
Market cap
$19.70B
P/E ratio
—
P/S ratio
1,479.80x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.5M
Roivant Sciences Ltd (ROIV) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | $1.39B | $2.48B | $2.69B | $2.59B | $2.39B | $7.22B | $5.44B |
| Cash & equivalents | $849.55M | $2.19B | $2.13B | $2.06B | $1.68B | $6.54B | $2.72B |
| Current assets | $1.19B | $2.22B | $2.19B | $2.15B | $1.80B | $6.73B | $5.00B |
| Total liabilities | $450.51M | $368.36M | $527.69M | $523.70M | $782.02M | $773.95M | $249.74M |
| Current liabilities | $211.27M | $92.12M | $218.96M | $184.37M | $272.45M | $266.76M | $149.41M |
| Long-term debt | — | — | $170.28M | $210.03M | $375.51M | $430.59M | — |
| Shareholder equity | $716.95M | $2.03B | $1.90B | $1.66B | $1.16B | $5.97B | $4.69B |
| Retained earnings | $-2.31B | $-1.11B | $-1.92B | $-2.76B | $-3.77B | $576.17M | $116.06M |
| Accounts receivable | $10.97M | $15.28M | $13.83M | $6.73M | $37.64M | $82.81M | — |
| Inventory | — | $1.00 | $63.87M | $-16.46M | $2.76M | $35.25M | — |
| Goodwill | — | — | — | — | — | — | — |